Pacer Advisors Inc. Invests $1.50 Million in Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• Pacer Advisors initiated a $1.5 million position in Arrowhead Pharmaceuticals, purchasing 23,922 shares during the first quarter. Institutional investors collectively own 62.61% of ARWR.
• Analyst sentiment remains generally positive: nine analysts rate the stock Buy, with a consensus “Moderate Buy” rating and an average price target of $97.33; several firms recently raised targets to between $98 and $123.
• Arrowhead reported quarterly revenue of $75.25 million, up 171% year over year and above estimates, but its $1.36 per-share loss missed expectations. Analysts still project a full-year loss, while some forecasts were lowered because profitability may be delayed.

Pacer Advisors Inc. purchased a new stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 23,922 shares of the biotechnology company's stock, valued at approximately $1,500,000.

A number of other large investors have also added to or reduced their stakes in ARWR. Geode Capital Management LLC grew its holdings in shares of Arrowhead Pharmaceuticals by 4.3% in the fourth quarter. Geode Capital Management LLC now owns 3,264,963 shares of the biotechnology company's stock valued at $216,799,000 after purchasing an additional 133,921 shares in the last quarter. Baker BROS. Advisors LP raised its stake in Arrowhead Pharmaceuticals by 30.2% during the fourth quarter. Baker BROS. Advisors LP now owns 2,175,645 shares of the biotechnology company's stock valued at $144,441,000 after purchasing an additional 504,883 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in Arrowhead Pharmaceuticals by 0.3% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 2,087,953 shares of the biotechnology company's stock valued at $138,619,000 after purchasing an additional 6,264 shares during the last quarter. Fred Alger Management LLC grew its stake in shares of Arrowhead Pharmaceuticals by 497.4% in the 4th quarter. Fred Alger Management LLC now owns 1,832,997 shares of the biotechnology company's stock worth $121,693,000 after buying an additional 1,526,164 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in shares of Arrowhead Pharmaceuticals by 34.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company's stock worth $22,189,000 after buying an additional 447,456 shares in the last quarter. Institutional investors own 62.61% of the company's stock.

Key Headlines Impacting Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $120 price target, well above recent trading levels. The firm also raised its FY2030 EPS forecast to $5.42 from $4.64, suggesting analysts still expect substantial earnings growth from Arrowhead’s pipeline and commercialization prospects. Analysts Offer Insights on Healthcare Companies
• Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to a loss of $3.45 from a loss of $3.75 and improved its Q4 2026 estimate to a loss of $1.35 from a loss of $1.51. These revisions point to somewhat better near-term results than previously expected.
• Neutral Sentiment: Arrowhead remains expected to report losses in FY2026 and FY2027, with consensus current-year EPS at a loss of $3.40. HC Wainwright’s forecast assumes profitability eventually emerges, including positive EPS in Q4 2027 and $5.42 EPS in FY2030.
• Negative Sentiment: HC Wainwright substantially reduced its EPS forecasts for FY2026, FY2027, FY2028 and FY2029, as well as Q1–Q4 2027. The FY2027 estimate was cut to a loss of $4.61 from $3.35, while the FY2028 estimate moved to a loss of $4.14 from $3.12. These revisions indicate greater expected spending or delayed revenue and could limit the stock’s gains.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ARWR. Stifel Nicolaus started coverage on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, July 14th. They set a "buy" rating and a $98.00 target price on the stock. Chardan Capital lifted their price target on Arrowhead Pharmaceuticals from $90.00 to $115.00 and gave the stock a "buy" rating in a research report on Wednesday, July 22nd. B. Riley Financial upped their price objective on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a "buy" rating in a research report on Thursday, July 30th. Weiss Ratings lowered Arrowhead Pharmaceuticals from a "hold (c-)" rating to a "sell (d-)" rating in a research note on Wednesday, May 20th. Finally, Morgan Stanley boosted their target price on Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the company an "overweight" rating in a research report on Thursday, July 23rd. Nine equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $97.33.

Arrowhead Pharmaceuticals Price Performance

ARWR stock opened at $87.65 on Friday. The stock has a market cap of $12.35 billion, a PE ratio of -38.96 and a beta of 1.27. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $15.01 and a 12 month high of $95.49. The company has a 50-day moving average price of $79.97 and a 200 day moving average price of $71.43. The company has a current ratio of 5.90, a quick ratio of 6.23 and a debt-to-equity ratio of 1.77.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.13). The firm had revenue of $75.25 million during the quarter, compared to analysts' expectations of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.The business's revenue for the quarter was up 171.0% compared to the same quarter last year. During the same period last year, the company earned ($1.26) earnings per share. Equities research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3.46 earnings per share for the current year.

Insider Activity at Arrowhead Pharmaceuticals

In other news, Director Hongbo Lu sold 2,970 shares of the stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total value of $228,333.60. Following the sale, the director directly owned 52,012 shares in the company, valued at approximately $3,998,682.56. This represents a 5.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.60% of the company's stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source